(POI), a multi-national, full service CRO to pharmaceutical and biotech industries achieved record growth in several areas in 2007
United States of America (Press Release) January 23, 2008 --
HOUSTON, TEXAS Jan. 23, 2008. Pharm-Olam International Ltd. (POI), a multi-national, full service CRO to pharmaceutical and biotech industries achieved record growth in several areas in 2007, including revenue and geographic coverage in addition to expansion of services.
POI has been awarded over $100 million in new contracts in 2007 across a variety of therapeutic areas. “Our increased business in 2007 has been achieved by continuing the sustained, organic growth that has served us so well in recent years. It is particularly gratifying to see that, in addition to some significant new pharma and biotech customers, our existing customers have also contributed to this growth by placing larger studies and entire programs of work with us”, said Iain Gordon, Vice President of Global Business Development. “We also experienced increased demand for our data management and biostatistics services which helped make for a record year.”
POI expanded its global reach in 2007 by adding regional offices in Princeton, USA and Novosibirsk, Russia to provide more cost-effective coverage of the Eastern U.S. and Central Russia. “Our global coverage continues to grow, however our decentralized business model remains the same, allowing us to start studies quickly and manage them efficiently”, said Gordon.
POI expanded its regulatory services by adding Sean Alan Reade as Vice President of Global Regulatory Affairs. Mr. Reade has over 25 years of experience and has directed the approval of 19 NDAs, 40 clinical SNDAs, and 7 MAAs for branded drug products across multiple therapeutic areas for both start-ups and global pharma. Sean Alan also filed the first full eCTD ever accepted by the EMEA.
For further information about Pharm-Olam please contact Iain Gordon at igordon@pharm-olam.com .
About Pharm-Olam International
Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From pre-clinical to Phase IV, POI focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines.
POI has been awarded over $100 million in new contracts in 2007 across a variety of therapeutic areas. “Our increased business in 2007 has been achieved by continuing the sustained, organic growth that has served us so well in recent years. It is particularly gratifying to see that, in addition to some significant new pharma and biotech customers, our existing customers have also contributed to this growth by placing larger studies and entire programs of work with us”, said Iain Gordon, Vice President of Global Business Development. “We also experienced increased demand for our data management and biostatistics services which helped make for a record year.”
POI expanded its global reach in 2007 by adding regional offices in Princeton, USA and Novosibirsk, Russia to provide more cost-effective coverage of the Eastern U.S. and Central Russia. “Our global coverage continues to grow, however our decentralized business model remains the same, allowing us to start studies quickly and manage them efficiently”, said Gordon.
POI expanded its regulatory services by adding Sean Alan Reade as Vice President of Global Regulatory Affairs. Mr. Reade has over 25 years of experience and has directed the approval of 19 NDAs, 40 clinical SNDAs, and 7 MAAs for branded drug products across multiple therapeutic areas for both start-ups and global pharma. Sean Alan also filed the first full eCTD ever accepted by the EMEA.
For further information about Pharm-Olam please contact Iain Gordon at igordon@pharm-olam.com .
About Pharm-Olam International
Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From pre-clinical to Phase IV, POI focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines.
Email
Print
SPAM
